Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage

Ndaya-Oloo, Paul; Pitisuttithum, Punnee; Tornieporth, Nadia; Desgrandchamps, Daniel; Kochhar, Sonali; Buttery, Jim; Bauwens, Jorgen; Bonhoeffer, Jan

doi:10.1002/jcph.1140

Cited by 7 publications

(8 citation statements)

References 76 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, IgG transfer from the mother to the fetus can occur from the 13th GWs, with the largest amount of transfer occurring during the third trimester of pregnancy. 46…”

Section: Types Of Vaccination Available During Pregnancymentioning

confidence: 99%

See 1 more Smart Citation

The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women

Wang

Lee

Yang

et al. 2021

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Effective strategies are urgently needed to decrease the risk of untoward outcomes of pregnant women with severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]) infection. Pregnant women are a vulnerable population to infectious disease pandemics with dramatically increased infectious diseases-related serious complications, such as the need of hospitalizations, the need of admission to intensive care unit, and the final disease-related death compared with those nonpregnant counterparts or those pregnant women without infection. Several studies have shown that vaccinations in pregnancy are a safe and highly effective strategy, not only for pregnant women but also for fetus and/or newborn because of the passive transplacental transfer of antibodies to the offspring. Active and passive prevention of infectious diseases is approved as effective strategies for women who attempt to become pregnant or during pregnancy. Despite the large and proven scientific evidence, pregnant women still puzzle over whether they should get vaccinated. The question therefore arises: Why are pregnant women so reluctant to receive vaccination? The explanation is more likely in the way that the benefits of vaccination have been communicated “confusedly.” In fact, like virtually all clinical trials, all the COVID-19 vaccine trials have excluded pregnant and lactating women from participating, contributing to uncertainty of safety and efficacy in COVID-19 vaccines that have been well prepared and available for the general adult population worldwide. Moreover, messenger RNA vaccine is a relatively brand-new vaccine, and experience with this type of vaccine is still scarce. It is hard to overcome this innovation deadlock. The knowledge and awareness of pregnant women who are at risk, and full information on the knowledge of vaccines and related preventable diseases in pregnant women may avoid hesitancy and increase vaccine acceptance. The current review is a part two addressing the impact of COVID-19 on pregnant women. We focus on the up-to-date information about the application of vaccination on pregnant women, especially during this COVID-19 pandemic.

show abstract

“…Furthermore, IgG transfer from the mother to the fetus can occur from the 13th GWs, with the largest amount of transfer occurring during the third trimester of pregnancy. 46…”

Section: Types Of Vaccination Available During Pregnancymentioning

confidence: 99%

“…Table 2 provides a summary of the vaccines that are often recommended in all women during the reproductive age, regardless of whether they are pregnant or not. 41,42,46–51 Table 3 lists the vaccinations that are indicated for medical needs during pregnancy. 41,42,46,47…”

Section: Types Of Vaccination Available During Pregnancymentioning

confidence: 99%

The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women

Wang

Lee

Yang

et al. 2021

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

show abstract

“…However, re-allocation measures remain ineffective in EU-wide shortages triggered by unexpectedly high demand (e.g., MMR-V vaccines in 2018 and influenza vaccines in the 2020/21), or in global supply constraints (e.g., polio and hepatitis A/B vaccines). Therefore, prevention of shortages requires (i) international collaboration to improve demand forecasting and distribution practices, (ii) international harmonisation of regulatory requirements to facilitate re-distribution, and (iii) new technological concepts to stabilise production processes and upscaling to keep pace with global demand [12][13][14]37,49].…”

Section: Table 3bmentioning

confidence: 99%

A 5-year look-back at the notification and management of vaccine supply shortages in Germany

et al. 2022

View full text Add to dashboard Cite

Background Unavailability of vaccines endangers the overall goal to protect individuals and whole populations against infections. Methods The German notification system includes the publication of vaccine supply shortages reported by marketing authorisation holders (MAH), information on the availability of alternative vaccine products, guidance for physicians providing vaccinations and an unavailability reporting tool to monitor regional distribution issues. Aim This study provides a retrospective analysis of supply issues and measures in the context of European and global vaccine supply constraints. Results between October 2015 and December 2020, the 250 notifications concerned all types of vaccines (54 products). Most shortages were caused by increased demand associated with immigration in Germany in 2015 and 2016, new or extended vaccine recommendations, increased awareness, or changes in global immunisation programmes. Shortages of a duration up to 30 days were mitigated using existing storage capacities. Longer shortages, triggered by high demand on a national level, were mitigated using alternative products and re-allocation; in a few cases, vaccines were imported. However, for long lasting supply shortages associated with increased global demand, often occurring in combination with manufacturing issues, few compensatory mechanisms were available. Nevertheless, only few critical incidents were identified: (i) shortage of hexavalent vaccines endangering neonatal immunisation programmes in 2015;(ii) distribution issues with influenza vaccines in 2018; and (iii) unmet demand for pneumococcal and influenza vaccines during the coronavirus disease (COVID)-19 pandemic. Conclusion Vaccine product shortages in Germany resemble those present in neighbouring EU states and often reflect increased global demand not matched by manufacturing capacities.

show abstract

“…Although healthcare systems around the world currently are fully absorbed with the day-to-day challenge of slowing down the spread of the SARS-CoV-2 virus, ongoing research makes it very likely that a protective vaccine will be developed within a rather short period of time [1,2]. It appears obvious that such a vaccine will not be available ad libitum right from the beginning [3], but rather that an initially short supply will meet a huge and desperate worldwide demand.…”

mentioning

confidence: 99%

Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

Henn

2020

Vaccine

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Commentary Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

show abstract

Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage

Cited by 7 publications

References 76 publications

The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women

The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women

A 5-year look-back at the notification and management of vaccine supply shortages in Germany

Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

Contact Info

Product

Resources

About